Saturday, March 29, 2025 | 07:27 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Glenmark defends pricing of Covid-19 drug FabiFlu, says it is economical

Glenmark also denies making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate Covid-19 patients

Glenmark defends pricing of Covid-19 drug FabiFlu, says it is economical
Premium

The company said that FabiFlu's price is significantly lower than versions of favipiravir in other countries.

Reuters New Delhi
Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu, on Tuesday, after India's drug regulator had reportedly sent the company a notice on overpricing.
Shares of the Mumbai-based company fell as much as 5.8 per cent on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns.

READ GLENMARK'S RESPONSE HERE
"Compared to other therapies approved for emergency use in Covid-19, FabiFlu is much more economical and an effective treatment option," the company said in a statement to the exchanges.
Glenmark

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in